MDGL Q4 2022 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$85M

Net Income

-$86M

EPS (Diluted)

$-4.98

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$363M

Total Liabilities

$165M

Stockholders' Equity

$197M

Cash & Equivalents

$332M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$85M	-$65M	-32.0%
Net Income	-$86M	-$65M	-33.1%